Sphingosine 1-phosphate (S1P) is a platelet-derived sphingolipid that elicits numerous biological responses in endothelial cells mediated by a family of G protein-coupled EDG receptors. Stimulation of EDG receptors by S1P has been shown to activate the endothelial isoform of nitric oxide synthase (eNOS) in heterologous expression systems (J Biol Chem 2000, 275: 32363).
However, the signaling pathways that modulate eNOS regulation by S1P/EDG in vascular endothelial cells remain less well understood. We now report that S1P treatment of bovine aortic endothelial cells (BAEC) acutely increases eNOS enzyme activity; the EC 50 for S1P activation of eNOS is ~10 nM. The magnitude of eNOS activation by S1P in BAEC is equivalent to that elicited by the agonist bradykinin. S1P treatment activates Akt, a protein kinase implicated in phosphorylation of eNOS. S1P treatment of BAEC leads to eNOS phosphorylation at Ser1179, a residue phosphorylated by Akt; an eNOS mutant in which this Akt phosphorylation site is inactivated shows attenuated S1P-induced eNOS activation. S1P-induced activation both of Akt and of eNOS is inhibited by pertussis toxin; by the phosphoinositide 3-kinase inhibitor wortmannin; and by the intracellular calcium chelator 1,2-bis-oaminophenoxyethane-N,N,N',N'-tetraacetic acid tetra(acetoxymethyl) ester.
By contrast to S1P, activation of G protein-coupled bradykinin B2 receptors neither activates kinase Akt nor promotes Ser1179 eNOS phosphorylation despite robustly activating eNOS enzyme activity. Understanding the differential regulation of protein kinase pathways by S1P and bradykinin may lead to the identification of new points for eNOS regulation in vascular endothelial cells.
Introduction
Vascular endothelial cells respond to intercellular messengers that modulate processes as diverse as blood pressure homeostasis, platelet aggregation and angiogenesis (reviewed in (1, 2) ). Blood platelets secrete sphingosine 1-phosphate (S1P), a biologically active sphingolipid that has been broadly implicated in angiogenesis, platelet activation, and inhibition of apoptosis in vascular cells (3, 4) . S1P has also been characterized as a potent signal transducing molecule that may exert such diverse biological responses as cellular differentiation (5, 6) , hypertrophy (7) , proliferation (8) , and migration (9) (10) (11) . S1P is a potent ligand for the G protein-coupled receptors termed EDG receptors (reviewed in (12) ). The EDG receptor family is comprised of at least 8 independent subtypes (EDG-1-8, see refs. (12) (13) (14) (15) ).
EDG receptors are coupled via pertussis toxin-sensitive G proteins to the activation of the mitogen-activated protein kinase (MAP kinase) pathway (16) and to the elevation of intracellular calcium concentration (10) in signal transduction pathways leading to angiogenesis (17) . Additionally, S1P
binding to the EDG-1 receptor has recently been shown to activate the endothelial isoform of nitric oxide synthase (eNOS) (18) , a key signaling protein that plays a pivotal role in the maintenance of vascular homeostasis by promoting vascular smooth muscle relaxation and inhibiting platelet aggregation (1).
The EDG-1 receptor and eNOS are both localized to plasmalemmal caveolae, which are specialized sphingolipid-enriched domains in the plasma membrane that serve as sites for the sequestration of diverse signaling proteins (18, 19) . However, the specific intracellular signaling pathways that couple S1P/EDG receptor stimulation to eNOS activation remain less well understood. eNOS is a calcium-calmodulin-dependent enzyme: in vascular endothelial cells, eNOS is activated in response to the transient increases in intracellular calcium initiated by the activation of diverse G protein-coupled receptors, including the bradykinin B2 receptor. eNOS is also activated by phosphorylation by protein kinase Akt (20, 21) , and eNOS is inhibited by the MAP kinases ERK1/2 (22) . eNOS phosphorylation by protein kinase Akt is promoted by vascular endothelial growth factor (VEGF) (20, 23) and by fluid shear stress (21, 24) , but Akt activation has not been previously implicated in eNOS regulation by G protein-coupled receptors. The protein kinase Akt (known also as protein kinase B; reviewed in (25) ) functions as a downstream effector of phosphoinositide 3-kinase (PI3-K)-dependent signaling pathways (reviewed in (26)), and plays pivotal roles in numerous cellular responses including angiogenesis (27) . Although G protein-coupled receptors may regulate the PI3-K/Akt pathway, the activation of Akt by S1P-induced EDG receptor stimulation has not been previously described.
In the present study, we provide evidence that S1P potently and robustly activates eNOS in cultured vascular endothelial cells via EDG receptors in a pathway that involves G protein-dependent activation of kinase Akt. eNOS activation by the S1P/EDG pathway stands in contrast to the activation of eNOS by bradykinin B2 receptors, in which activation of eNOS appears to proceed independently of Akt-mediated phosphorylation.
Experimental Procedures

Materials.
Fetal bovine serum (FBS) was from Hyclone (Logan, CT); all other cell culture reagents, media and LipofectAMINE were from Life Technologies (Rockville, MD). S1P and dihydro-S1P (sphinganine 1-phosphate) were from 
Plasmid construction.
cDNA encoding full-length human EDG-1 receptor epitope-tagged with FLAG peptide (FLAG/EDG-1, described in (16) , was provided by Timothy Hla, University of Connecticut) was subcloned into pcDNA3 (Invitrogen) as previously described (18) . Full-length wild type bovine eNOS cDNA subcloned into pBK-CMV was described previously (28) . eNOS S1179A mutant cDNA was made with PCR-based mutagenesis and verified with standard DNA sequencing technique (22) .
Cell Culture, Transfection and Drug Treatment.
BAEC were obtained from Cell Systems (Kirkland, WA), and maintained in culture in Dulbecco's modified Eagle media (DMEM) supplemented with FBS (10%, v/v) as described (29) . Cells were plated onto gelatin-coated culture dishes and studied prior to cell confluence between passages 5 -9.
COS-7 cells were maintained in culture as described previously (30) .
The day before transfection, cells were split at a ratio of 1:8 in DMEM containing 10% FBS. They were then co-transfected with cDNAs encoding FLAG/EDG-1 (2 µg) and/or eNOS (0.03 µg) by using LipofectAMINE, as previously described (18) . The total DNA amount was normalized using 
Western Blot Analyses.
Protein expression and the degree of protein phosphorylation were assayed by the western blot analysis. After drug treatments, cells in a 60 mm dish were washed with ice-cold PBS and incubated for 10 min on ice with 500 µl of lysis buffer containing: Tris (20 mM; pH 7.5), EDTA (1 mM), EGTA (1 mM), Triton-X (1%, v/v), NaCl (150 mM), Na 3 VO 4 (1 mM), sodium pyrophosphate (2.5 mM), ß-glycerophosphate (1 mM) and a cocktail of protease inhibitors (as described in (31)). Cells were harvested by scraping and centrifuged at 4 o C for 10 min in a microfuge. The supernatant was analyzed for protein concentration, and an equal amount of cellular proteins (20 µg/lane) were separated by SDS-PAGE and transferred to a nitrocellulose membrane.
The membrane was then probed with the appropriate primary antibody: membrane-bound primary antibodies were visualized by using secondary antibodies conjugated with horseradish-peroxidase and Super Signal substrate, as previously described (32) . Densitometric analyses of western blots were performed using a ChemiImager 4000 (Alpha-Innotech).
Immuno-Kinase Assay.
The enzyme activity of Akt or ERK1/2 in BAEC was determined in vitro by using commercially available kinase activity kits following the supplier's protocol. Briefly, an equal amount (70 µg) from each cell lysate described 
Other methods.
All experiments were performed at least 3 times. Mean values for individual experiments are expressed as mean ± S.E.M. Statistical differences were analyzed by ANOVA followed by Scheffe's F test using STAT VIEW II (Abacus Concepts). A p value less than 0.05 was considered statistically significant.
Results
We first studied the responses of BAEC to S1P by analyzing the effects of S1P on activation of protein kinases Akt and ERK1/2 ( Figure 1 ). We exploited two independent experimental approaches to assess Akt or ERK activation in BAEC: we analyzed immunoblots probed with antibodies that specifically detect the phosphorylated (activated) forms of these kinases, and also performed in vitro kinase activity assays using protein substrates specific for kinases Akt and ERK. Note that the activation of these kinases is accompanied by the phosphorylation of specific amino acid residues in these proteins (25, 36) . Following the addition of S1P (100 nM) to BAEC, we detected increases in Akt phosphorylation as well as Akt enzyme activity within 1 min, reaching a maximum ~4 fold increase in activity by 2-5 min, with a gradual return to basal levels seen at 120 min following drug addition ( Figure 1 ). Immunoblot analyses probed with an anti-Akt antibody were used to verify that these cell lysates contain equivalent amounts of Akt protein.
The MAP kinases ERK1/2 also undergo robust and rapid phosphorylation and kinase activation following addition of S1P to BAEC; ERK1/2 activity and phosphorylation levels returned to the basal within 20 min following S1P addition ( Figure 1 ). In these same cell lysates from S1P-treated BAEC, we analyzed immunoblots probed with an antibody raised against a phosphopeptide comprising the eNOS amino acid sequence around Ser1179 ( 1179 S), the site at which eNOS undergoes phosphorylation by kinase Akt (20, 21) . As shown in Figure 1 , S1P treatment of BAEC markedly increased eNOS phosphorylation at Ser1179, with a time course similar to that seen for Akt activation.
We next analyzed the dose response to S1P for Akt and ERK1/2 activation as well as 1179 S-phospho-eNOS formation in BAEC treated for 5 min with increasing concentrations of S1P. Figure 2A To further characterize S1P-induced Akt and ERK activation as well as 1179 S-phospho-eNOS formation, BAEC were treated with various inhibitors prior to the addition of S1P. As shown in Figure 3 , pretreatment with pertussis toxin completely abolished S1P-induced Akt and ERK1/2 activation as well as 1179 S-phospho-eNOS synthesis, indicating that the effects of S1P are dependent upon the activation of pertussis toxin-sensitive G protein pathways. Interestingly, the intracellular calcium chelator BAPTA completely inhibited Akt activation and 1179 S-phospho-eNOS synthesis, suggesting that activation of the PI3-K/Akt pathway by S1P is dependent upon the elevation of intracellular calcium concentration (Figure 3 ). In contrast, BAPTA did not block S1P-induced ERK1/2 activation; rather, calcium chelation with BAPTA led to a marked increase in the phosphorylation of these MAP kinase pathway proteins. Wortmannin, an inhibitor of PI3-K (an upstream activator of Akt), blocked S1P-mediated Akt activation and 1179 S-phospho-eNOS formation, but did not inhibit S1P-mediated activation of ERK1/2 ( Figure 3) . In contrast to the effects of wortmannin, the kinase inhibitor PD98059 (which inhibits the MAP kinase kinase MEK, which in turn phosphorylates ERK1/2), abolished ERK1/2 activation by S1P, but blocked neither S1P-mediated activation of Akt nor 1179 S-phospho-eNOS synthesis (Figure 3 ). These experiments demonstrate that the S1P-mediated activation of Akt and ERK1/2 and the formation of 1179 S-phospho-eNOS are mediated by pertussis toxin-sensitive G proteins, and that Akt activation and 1179 S-phospho-eNOS formation are calciumdependent whereas ERK1/2 activation is not.
We next examined features of S1P-mediated eNOS activation in BAEC. Figure 4A shows the results of a S1P dose-response experiment in which cellular eNOS activity was quantitated by measuring the formation of We further explored the relationships between S1P-induced kinase activation and S1P-modulated eNOS activation by performing transient transfection experiments using cDNA constructs encoding eNOS and EDG-1 in COS-7 cells, following previously described co-transfection protocol (18) .
It is of note that COS-7 cells do not express endogenous EDG-1 receptors (37). We studied wild-type eNOS cDNA as well as an eNOS mutant in which the putative kinase Akt phosphorylation site 1179 Ser is changed to Ala (S1179A) (20) (21) (22) in cotransfection experiments with a cDNA construct encoding the EDG-1 receptor epitope-tagged with FLAG peptide (FLAG/EDG-1). Note that this epitope-tagged receptor construct retains essential features of wild type EDG-1 receptor (5,16,18,38) . COS-7 cells transiently expressing FLAG/EDG-1 and/or eNOS cDNAs were treated with S1P (100 nM, 5 min); cell lysates were probed by western blot analysis with various antibodies, as shown in Figure 5 . The overall expression of endogenous kinase Akt protein was unaffected by cDNA transfections; expression levels of the variously transfected cDNAs were concordant with the specific cDNA constructs used in these experiments ( Figure 5A ). S1P treatment induces the phosphorylation (activation) of Akt only in cells transfected with the EDG-1 cDNA. Similarly, 1179 S-phospho-eNOS formation is observed only when S1P is added to cells co-transfected with EDG-1 and wild-type eNOS cDNAs. Importantly, when cells are cotransfected with EDG-1 and the S1179A mutant eNOS, S1P-induced 1179 Sphospho-eNOS formation was not detected despite robust phosphorylation of Akt ( Figure 5A ). We next examined the effects of S1P on eNOS activation in these cells. COS-7 cells transiently expressing FLAG/EDG-1 and eNOS cDNAs (wild type or S1179A) were incubated with [ 3 H] L-arginine and treated with S1P or vehicle; cells were harvested and lysates were analyzed for [ 3 H] L-citrulline formation as described above. As we have observed previously (18) , S1P activates eNOS in cells co-transfected with FLAG/EDG-1 and wild type eNOS, with an EC 50 of ~20 nM ( Figure 5B ). In cells co-transfected with the S1179A eNOS mutant plus EDG-1, there is a markedly attenuated response to S1P compared with wild type eNOS ( Figure   5B ), despite the fact that these cells express eNOS protein at equivalent levels ( Figure 5A ).
We next explored the differential regulation of S1P-mediated responses by directly comparing the signaling pathways elicited by S1P with those activated by bradykinin, a well known activator of eNOS in BAEC (39) . As shown in Figure 6A , bradykinin (1 µM) induces the activation (phosphorylation) of ERK1/2 in BAEC, as we have reported previously ( Figure 6A , (22)). However, bradykinin does not induce the activation of Akt or formation of 1179 S-phospho-eNOS, although the same cell preparations respond to S1P ( Figure 6A ). We compared bradykinin and S1P-mediated eNOS activation in BAEC, as shown in Figure 6B . Although bradykinin and S1P both activate eNOS to a similar extent, bradykinin-induced eNOS activation is not inhibited by pertussis toxin nor by wortmannin, in contrast to the inhibitory effects of these agents on S1P-mediated eNOS activation.
PD98059 has no substantive effect on bradykinin-dependent eNOS activation in this experimental system. It is notable that bradykinin and S1P activate eNOS to a similar magnitude ( Figure 6B ). When cells are treated with both bradykinin and S1P in combination, there is no additive increase in eNOS activity compared to cells treated individually with bradykinin or S1P.
Discussion
These studies have provided several lines of evidence demonstrating that S1P induces eNOS activation in cultured endothelial cells, at least in part mediated by eNOS Ser1179 phosphorylation and involving the PI3-K/Akt pathway. As shown in Figure 1 , the addition of S1P rapidly activates Akt kinase and ERK1/2, concomitant with eNOS phosphorylation on serine 1179. S1P-mediated Akt activation and eNOS 1179 S-phosphorylation persists for up to two hours, whereas ERK1/2 phosphorylation returns to basal levels Concentrations of S1P in human blood have been measured in the range of several hundred nanomolar (40) . However, the extent to which extracellular S1P may be protein-bound (or otherwise complexed) has not been rigorously determined, such that the concentration of free "biologically active" S1P available for interaction with EDG receptors may be considerably lower.
Moreover, local blood concentrations of S1P may acutely increase when the compound is released from activated platelets (4, 40) , suggesting that levels of S1P may be subject to physiological regulation. Thus, the potency of S1P in The present study provides the first evidence that G protein-coupled receptor stimulation can lead to Akt-dependent eNOS phosphorylation.
However, not all of S1P's effect on eNOS activation is due to eNOS 1179 Sphosphorylation: as shown in Figure 5 , the S1179A eNOS mutant still undergoes S1P-dependent activation (albeit less than the wild-type enzyme), and the PI3-K inhibitor wortmannin only partially blocks S1P-induced eNOS activation (Figure 4) , while this inhibitor completely blocks S1P-induced Akt activation (Figure 3) . These results also point up key differences between two different G protein-coupled receptors, the EDG receptor pathway activated by S1P, and B2 receptor pathway activated by bradykinin. In contrast to S1P, bradykinin does not activate Akt kinase nor promote eNOS 1179 S-phosphorylation ( Figure 6 ). However, bradykinin still promotes robust activation of eNOS to levels comparable to S1P without appearing to involve the PI3-K pathway. S1P and EDG receptors are implicated in signal transduction pathways leading to angiogenesis (17) . Interestingly, eNOS and PI3-K/Akt are also independently implicated in angiogenesis. For example, angiogenic polypeptide growth factors such as VEGF lead to eNOS enzyme activation (48, 49) , and overexpression of a dominant-negative PI3-K construct markedly attenuates angiogenesis (27) . Moreover, these signaling molecules share common features of their subcellular localization: plasmalemmal caveolae serve as the sites for localization of eNOS (19) , EDG-1 receptor 
